Clinical outcomes associated with changes in a chronic disease treatment program in an Australian aboriginal community

Medical Journal of Australia

Volumn 183, Issue 6, 2005, Pages 305-309

  Hoy, Wendy E ^a   Kondalsamy Chennakesavan, Srinivas N ^a   Nicol, Jennifer L ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PERINDOPRIL;

ABORIGINE; ADULT; ARTICLE; BEHAVIOR MODIFICATION; BLOOD PRESSURE REGULATION; CHRONIC DISEASE; DIABETES MELLITUS; ETHNOLOGY; FEMALE; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH PROGRAM; HEALTH PROMOTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LIFESTYLE; MALE; MEDICAL DECISION MAKING; MEDICAL INFORMATION SYSTEM; MORTALITY; PATIENT CARE; PATIENT COMPLIANCE; RISK ASSESSMENT;

EID: 25144488714     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2005.tb07060.x     Document Type: Article

References (27)

1. Spencer JL, Silva DT, Snelling P, Hoy WE. An epidemic of renal failure among Australian Aboriginals. Med J Aust 1998; 168: 537-541.
2. McDonald SP, Russ GR. Current incidence, treatment patterns and outcome of end-stage renal disease among indigenous groups in Australia and New Zealand. Nephrology (Carlton) 2003; 8: 42-48.
3. Australian Bureau of Statistics. The health and welfare of Australia's Aboriginal and Torres Strait Islander peoples. Canberra: ABS, 2001. (ABS Catalogue No. 4704.0.)
4. Hoy WE, Mathews JD, McCredie DA, et al. The multidimensional nature of renal disease: rates and associations of albuminuria in an Australian Aboriginal community. Kidney Int 1998; 54: 1296-1304.
5. Hoy WE, Wang Z, VanBuynder P, et al. The natural history of renal disease in Australian Aborigines. Part 1. Changes in albuminuria and glomerular filtration rate over time. Kidney Int 2001; 60: 243-248.
6. McDonald SP, Wang Z, Hoy WE. Physical and biochemical predictors of death in an Australian aboriginal cohort. Clin Exp Pharmacol Physiol 1999; 26: 618-621.
7. Hoy WE, Wang Z, VanBuynder P, et al. The natural history of renal disease in Australian Aborigines. Part 2. Albuminuria predicts natural death and renal failure. Kidney Int 2001; 60: 249-256.
8. Hoy WE, McFarlane R, Pugsley DJ, et al. Markers for cardiovascular and renal morbidity: expectations for an intervention programme in an Australian aboriginal community. Clin Exp Pharmacol Physiol 1996; 23(8): S33-S37.
9. Hoy WE, Kelly A, Jacups S, McKendry K, et al. Stemming the tide: reducing cardiovascular disease and renal failure in Australian Aborigines. Aust N Z J Med 1999; 29: 480-483.
10. Hoy WE, Baker PR, Kelly AM, Wang Z. Reducing premature death and renal failure in Australian Aboriginals. A community-based cardiovascular and renal protective program. Med J Aust 2000; 172: 473-478.
11. Hoy WE, Wang Z, Baker PR, Kelly AM. Reduction in natural death and renal failure from a systematic screening and treatment program in an Australian Aboriginal community. Kidney Int Suppl 2003; 83: S66-S73.
12. You J, Hoy WE, Zhao Y, et al. End-stage renal disease in the Northern Territory: current and future treatment costs. Med J Aust 2002; 176: 461-465.
13. Baker PR, Hoy WE, Thomas RE. Cost-effectiveness analysis of a kidney and cardiovascular disease treatment program in an Australian Aboriginal population. Adv Chronic Kidney Dis 2005; 12: 22-31.
14. Kondalsamy-Chennakesavan S. Sustaining renal health outcomes following a community-based intervention program [MPH thesis]. Darwin: Northern Territory University 2003.
15. Robinson GB, Wang Z, Snelling P, Kondalsamy-Chennakesavan S. A follow-up study of outcomes of the Tiwi renal treatment program. Darwin: Northern Territory University, 2003.
16. Hoy WE, Kondalsamy-Chennakesavan S, Scheppingen J, Sharma S, McKendry K. Final report on the Aboriginal Chronic Disease Outreach Program, submitted to Kidney Health Australia and the Office of Aboriginal and Torres Strait Islander Health. Brisbane: Centre for Chronic Disease, University of Queensland, 2003.
17. Hoy WE, Kondalsamy-Chennakesavan S, Scheppingen J, Sharma S. Kidney and related chronic disease profiles and risk factors in three remote Australian Aboriginal communities. Adv Chronic Kidney Dis 2005; 12: 64-70.
18. Von Korff M, Gruman J, Schaefer J, et al. Collaborative management of chronic illness. Ann Intern Med 1997; 127: 1097-1102.
19. Kotter JP. What leaders really do. Harvard Business Review 1990; 68(3): 103-111.
20. Davey RG, Gokel G, Hoy WE. Obstacles to good management of chronic disease in remote Aboriginal Australia. Nephrology 2002; 7 Suppl: A78.
21. Hoy WE, Kondalsamy-Chennakesavan S, Scheppingen J. Western Australian Chronic Disease Outreach Program. Annual report for the year 2004. Brisbane: Centre for Chronic Disease, University of Queensland, 2005.
22. Hoy WE, Chennakesavan Kondalsamy S. A simplified approach to renal and cardiovascular protection for Aboriginal people with type 2 diabetes [abstract of poster]. Nephrology (Carlton) 2004; 9 Suppl 1: 3A80.
23. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342: 145-153.
24. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419.
25. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117-124.
26. Kincaid-Smith P, Fairley K, Packham D. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant 2002; 17: 597-601.
27. Wagner EH, Davis C, Schaefer J, et al. A survey of leading chronic disease management programs: are they consistent with the literature? Manag Care Q 1999; 7: 56-66.